1. Cardiovascular risk in HIV/AIDS and Lipodystrophy Syndrome patients
- Author
-
Celso Ferreira Filho, Karina Viviani de Oliveira Pessôa, Renata Macedo Martins Pimentel, Mariliza Henrique da Silva, Adriano L. Roque, Valdelias Xavier Pereira, Luiz Carlos de Abreu, Rubens Wajnsztejn, Vitor Engrácia Valenti, Laércio da Silva Paiva, Celso Ferreira, Francisco Winter do Santos Figueiredo, Fernando Rocha Oliveira, Tatiana Dias de Carvalho, and Fernando Adami
- Subjects
medicine.medical_specialty ,Aids patients ,Framingham Risk Score ,business.industry ,Human immunodeficiency virus (HIV) ,virus diseases ,General Medicine ,Disease ,medicine.disease ,medicine.disease_cause ,Antiretroviral therapy ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Physical therapy ,Medicine ,In patient ,Lipodystrophy ,business - Abstract
Background: The treatment of people living with AIDS , known a highly active antiretroviral therapy (HAART), has increased considerably, and the disease has therefore acquired chronic features. Several changes have been observed, especially in cardiovascular disease risk. Objective: To assess cardiovascular risk in HIV/AIDS patients treated with HAART and compare this with Lipodystrophy Syndrome (LS) carriers. Methods: This is a descriptive cross-sectional study. 192 patients were recruited from a lipodystrophy outpatient centre, using Framingham risk scores. Results: After criteria inclusion/exclusion, the final sample consisted of 81 patients divided into two groups (HIV/AIDS - without lipodystrophy and HIV/LS - with lipodystrophy). The mean age of HIV/AIDS was 46.5 years, and of the HIV/LS patients was 52 years. In accordance with Framingham scores the cardiovascular risk in HIV/AIDS was 46.59% and 14.29% in HIV/LS. Conclusion: The risk of cardiovascular disease over 10 years is significantly higher in patients with lipodystrophy syndrome.
- Published
- 2015